US Scalp-Serum Claims: Keep Cosmetic Care Separate from Hair-Growth Treatment
Review US scalp-serum claims before labeling. Separate cosmetic appearance and care language from hair-growth or disease-treatment positioning.
Direct answer: Review the product’s intended use and public wording before positioning a US scalp serum. Cosmetic care language and hair-growth or disease-treatment claims can lead to different regulatory requirements; an OEM label does not determine classification.
Check the whole public message
FDA explains that claims and intended use can make a product a drug, even if presented as a cosmetic. Hair-growth and dandruff-treatment positioning need particular attention. Review website copy and advertising as well as the physical label.
Keep the brief concrete
State whether the product is intended for cosmetic hydration, feel or appearance, and request evidence for the exact wording. Do not replace a missing result with “clinically inspired,” “cosmeceutical” or a medical-looking package. Those phrases do not resolve classification or substantiation.
Use the right review before release
Have the responsible US-market specialists assess the product, ingredients, label and proposed claims. Keep the resulting approved wording with the formula version. This article identifies a buying question; it does not certify the product or establish a permitted drug claim.
Create a claim-to-evidence table before artwork
Put each proposed label or website statement in a separate row with its intended meaning, relevant product version, supporting evidence and US-market reviewer. Cosmetic conditioning and appearance should not be mixed casually with restoring growth or treating a scalp disorder. FDA’s official guidance, checked 25 October 2026, treats intended use as central to classification and considers online promotional claims as well as packaging.
Separate the three procurement gates
Gate one: identify the intended cosmetic role and exact formula. Gate two: review the evidence for the proposed wording. Gate three: obtain the appropriate US classification, label and ingredient assessment. A study on an ingredient does not automatically substantiate the finished serum, and a finished-product study does not automatically resolve classification. This is a procurement framework, not a legal determination for an individual product.
Keep the linked serum specification identifiable
The linked JunChun serum page shows a 60 ml dropper presentation and discusses a water-serum direction. Use its actual approved sample identity when requesting documentation. Ask the team to connect the formula, pack, usage instructions and permitted project claims in one version-controlled brief. Do not borrow another brand’s hair-growth endpoint or claim merely because the same ingredient name appears.
A practical buying decision
| Decision point | What to request or compare |
|---|---|
| Intended use | Identify the actual promised benefit. |
| Public copy | Review label, website and advertising together. |
| Release | Use market-specific approval and evidence records. |
JunChun product and project options
Discuss the current formula, sample and packaging options with JunChun for your target market. Selected mature formulas with qualified stock packaging can start at 100 pieces per SKU. Packaging changes start from 500, subject to actual process minimums. Formula changes, specialist dispensers and printing require a project-specific review.
Frequently asked questions
Can an ingredient study authorize a US hair-growth cosmetic claim?
No. Evidence and regulatory classification are separate questions.
Is “FDA approved cosmetic” a suitable shortcut?
Do not use an unsupported approval claim. Request the actual applicable regulatory information.
What should I include in a sample enquiry?
Send your US product positioning, proposed claims and current formula specification, destination country and planned quantity. Ask which current samples or development options fit those requirements.
Related products and manufacturing
Discuss your product brief
Send your US product positioning, proposed claims and current formula specification, destination country and planned quantity. Include the current benchmark or sample code so JunChun can compare the appropriate route. Request product options and a project review or email info@junchunbeauty.com.
Sources and scope
- FDA: Is It a Cosmetic, a Drug, or Both? — Official guidance accessed 2026-10-25. Official US classification guidance
Reviewed 25 October 2026. Buying frameworks and screening steps are recommendations, not reported JunChun test results or guarantees of demand, compliance or performance.
